BioAtla, Inc. (BCAB)
BCAB moved a median of -0.56% 30 minutes after news, and -1.34% by the close. How BCAB actually reacts to news — the realized, point-in-time move the market made, measured across 246 labeled events over the last three years with zero look-ahead.
BCAB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.14% | 42% | 245 |
| 30-min | -0.56% | 42% | 246 |
| 60-min | -1.36% | 38% | 246 |
| to close | -1.34% | 42% | 246 |
| Middle 50% of BCAB reactions | -3.33% to +1.74% |
|---|---|
| Median reaction (30-min) | -0.56% |
| Measured reactions | 246 |
Half of all BioAtla, Inc. news events land between -3.33% and +1.74% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when BCAB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BCAB's baseline. Nothing else.
Recent BCAB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K BioAtla, Inc. For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -10.35% | |
| Form 8-K BioAtla, Inc. For: Aug 26 | SEC filing · Form 8-K | SEC EDGAR | +12.66% | +9.81% | |
| Form 10-Q BioAtla, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.92% | -9.91% | |
| Form 8-K BioAtla, Inc. For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.50% | |
| Form ARS BioAtla, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.88% | +2.05% | |
| Form DEF 14A BioAtla, Inc. For: Jun 03 | SEC filing · Form DEF | SEC EDGAR | +0.88% | +2.05% | |
| Form DEFA14A BioAtla, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.88% | +2.05% | |
| Form 10-Q BioAtla, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.70% | -8.84% | |
| Form 10-K/A BioAtla, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +1.94% | |
| Form 8-K BioAtla, Inc. For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | -14.72% | -13.34% | |
| BioAtla Announces Share Consolidation | Press release | GlobeNewswire | -2.58% | +8.37% | |
| BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights | Press release | GlobeNewswire | -2.58% | +8.37% | |
| Form 10-K BioAtla, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.58% | +8.37% | |
| Form 8-K BioAtla, Inc. For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | -2.58% | +8.37% | |
| Form S-8 BioAtla, Inc. | SEC filing · Form S-8 | SEC EDGAR | -2.58% | +8.37% | |
| Form 8-K BioAtla, Inc. For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | -2.35% | -12.88% | |
| BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets | Press release | GlobeNewswire | -3.67% | +5.37% | |
| Form 8-K BioAtla, Inc. For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | -3.67% | +5.37% | |
| Form DEFA14A BioAtla, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -3.67% | +5.37% | |
| Form DEFM14A BioAtla, Inc. | SEC filing · Form DEFM14A | SEC EDGAR | -2.61% | -8.50% | |
| Form 8-K BioAtla, Inc. For: Feb 08 | SEC filing · Form 8-K | SEC EDGAR | +5.42% | +0.00% | |
| Form 8-K BioAtla, Inc. For: Feb 06 | SEC filing · Form 8-K | SEC EDGAR | +5.42% | +0.00% | |
| Form 8-K BioAtla, Inc. For: Jan 26 | SEC filing · Form 8-K | SEC EDGAR | -36.00% | -30.68% | |
| Form PREM14A BioAtla, Inc. For: Jan 30 | SEC filing · Form PREM14A | SEC EDGAR | -36.00% | -30.68% | |
| Form S-3 BioAtla, Inc. | SEC filing · Form S-3 | SEC EDGAR | +2.73% | -2.85% | |
| Form DEFA14A BioAtla, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.01% | +0.82% | |
| Form 8-K BioAtla, Inc. For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | +4.11% | -6.18% | |
| BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) | Press release | GlobeNewswire | -7.41% | -30.60% | |
| Form 8-K BioAtla, Inc. For: Dec 30 | SEC filing · Form 8-K | SEC EDGAR | -7.41% | -30.60% | |
| Form DEFA14A BioAtla, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -3.61% | -13.84% | |
| Form 8-K BioAtla, Inc. For: Dec 30 | SEC filing · Form 8-K | SEC EDGAR | -7.41% | -30.60% | |
| Form DEF 14A BioAtla, Inc. For: Dec 05 | SEC filing · Form DEF | SEC EDGAR | -2.02% | -4.85% | |
| Form PRE 14A BioAtla, Inc. For: Nov 24 | SEC filing · Form PRE | SEC EDGAR | -1.98% | -6.66% | |
| BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing | Press release | GlobeNewswire | -1.72% | -25.07% | |
| Form 8-K BioAtla, Inc. For: Nov 20 | SEC filing · Form 8-K | SEC EDGAR | -1.72% | -25.07% | |
| BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas | Press release | GlobeNewswire | +3.13% | +7.28% | |
| BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025 | Press release | GlobeNewswire | -2.86% | -6.37% | |
| BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society | Press release | GlobeNewswire | -1.25% | +4.04% | |
| BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025 | Press release | GlobeNewswire | +10.07% | -11.12% | |
| BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 | Press release | GlobeNewswire | +0.78% | +4.05% | |
| Form 8-K BioAtla, Inc. For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | -0.90% | -7.34% | |
| BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA | Press release | GlobeNewswire | +0.00% | +13.19% | |
| BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress | Press release | GlobeNewswire | +1.78% | -3.58% | |
| Form 10-Q BioAtla, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.78% | -3.58% | |
| Form 8-K BioAtla, Inc. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +1.78% | -3.58% | |
| BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025 | Press release | GlobeNewswire | -1.37% | -5.23% | |
| BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting | Press release | GlobeNewswire | -0.61% | -4.97% | |
| BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastro | Press release | GlobeNewswire | +0.05% | -1.03% | |
| Form 8-K BioAtla, Inc. For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +4.62% | +5.56% | |
| BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen | Press release | GlobeNewswire | +3.50% | +22.77% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BCAB section they belong to.
Where else BCAB is measured.
BCAB earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is BioAtla, Inc.'s median reaction calculated?
Every labeled BCAB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 246 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of BCAB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BCAB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.